National Poliomyelitis Response Plan for New Zealand

Source: New Zealand Ministry of Health

New Zealand has been declared polio free, with the last case occurring in 1977. This plan sets out the response in New Zealand to a potential first case of imported wild-virus polio. While it is unlikely poliovirus would spread significantly if it came to New Zealand, the public health system needs to be ready with a response that is prompt, effective, and based on available evidence should this unlikely event occur.

The plan complements the chapter on poliomyelitis in the Ministry of Health’s Communicable Diseases Control Manual by providing more detail.

 

Ngā Wānanga Pae Ora 2023 – Summary Report

Source: New Zealand Ministry of Health

Summary

In July 2023, six Pae Ora | Healthy Futures Strategies were released, setting the direction for a New Zealand health system that is equitable, accessible, cohesive and people-centred.

Ngā Wānanga Pae Ora 2023 – Summary Report uplifts the voices of Māori communities, whānau, hapū, iwi, health sector groups, and community organisations who helped to shape those strategies – in particular Pae Tū: Hauora Māori Strategy.

The challenges to the health system, peoples’ experiences of it and their hopes for the future played a critical role in determining the Māori priorities for Pae Tū.

This report summarises the key themes, priorities, and reflections that emerged from wānanga with Māori communities, iwi, and Māori health sector partners around the country, led by Manatū Hauora and Te Aka Whai Ora.

These wānanga, called ‘Ngā Wānanga Pae Ora’, were the main avenue through which whānau and the Māori health sector could share their aspirations for the Pae Ora strategies. Another pathway was through the whānau voice hui led by Te Aka Whai Ora.

Ngā Wānanga Pae Ora 2023: Summary Report reflects our commitment to working with partners and audiences, to deliver strategies that honour their aspirations.

Office of the Director of Mental Health and Addiction Services Regulatory Report 1 July 2021 to 30 June 2022

Source: New Zealand Ministry of Health

The Office of the Director of Mental Health and Addiction Services Regulatory Report 1 July 2021 to 30 June 2022 provides information and statistics relating to the use of compulsory assessment and treatment legislation in Aotearoa New Zealand.

For more mental health and addiction data, please see Mental health and addiction data.

The legislation covered includes the Mental Health (Compulsory Assessment and Treatment) Act 1992, Intellectual Disability (Compulsory Care and Rehabilitation) Act 2003, and the Misuse of Drugs Act 1975. It includes subjects such as the use of seclusion, compulsory treatment orders, and electroconvulsive therapy (ECT).

Maximum numbers of approved smoked tobacco retail premises permitted in areas of New Zealand

Source: New Zealand Ministry of Health

Currently there are around 6,000 retail stores selling smoked tobacco products in Aotearoa. New legislation under the Smokefree Environments and Regulated Products Act 1990 will restrict the sale of these products to no more than 599 outlets under the Smoked Tobacco Retail Scheme. Retailers who want to become an Approved Smoked Tobacco Retailer (ASTR) so they can legally sell smoked tobacco products from 1 July 2024, must submit an application to the Tobacco Regulatory Authority.  The scheme will open for applications on 21 September 2023, further information will be available shortly.

In setting the maximum numbers per area, the Director-General of Health was required to take into account the size of the population in an area, the estimated number of people who smoke, the geographic nature of the area and estimated average travel times. As required by the Act, consultation was undertaken with the Māori Health Authority (Te Aka Whai Ora), iwi-Māori partnership boards, any iwi whose rohe includes all or part of a proposed area, and any other Māori who the Director-General considered appropriate. This targeted consultation was undertaken in early 2023, alongside consultation on other regulatory proposals, running in parallel with the wider public consultation. 

The maximum numbers of approved smoked tobacoo retail premises permitted in areas of New Zealand are set out in the following tables.

Urban areas
Area Number Area Number
Auckland 25 New Plymouth 5
Airside – Auckland International Airport 1 Ngāruawāhia 2
Airside – Christchurch International Airport 1 Ngongotahā 2
Airside – Queenstown International Airport 1 Oamaru 3
Airside – Wellington International Airport 1 Ōhope 1
Alexandra 2 Omokoroa 1
Amberley 1 One Tree Point 1
Arrowtown 1 Ōpōtiki 2
Ashburton 3 Ōtaki 1
Ashhurst 1 Ōtaki Beach 1
Balclutha 2 Otorohanga 1
Beachlands-Pine Harbour 2 Oxford 1
Blenheim 4 Paekākāriki 1
Bluff 1 Paeroa 2
Brightwater 1 Pahiatua 1
Bulls 1 Paihia/Kawakawa/Moerewa 2
Cambridge 3 Palmerston North 6
Carterton 1 Paraparaumu 3
Christchurch 13 Pegasus 1
Clive 1 Picton 1
Coromandel 1 Pōkeno 1
Cromwell 2 Porirua 6
Dannevirke 2 Prebbleton 1
Darfield 1 Pukekohe 3
Dargaville 2 Putāruru 2
Dunedin 6 Queenstown 2
Edgecumbe 1 Raglan 1
Eltham 1 Rangiora 3
Featherston 1 Renwick 1
Feilding 3 Richmond 2
Foxton 1 Riverhead 1
Foxton Beach 1 Rolleston 2
Geraldine 1 Rotorua 6
Gisborne 5 Ruakākā 1
Gore 2 Snells Beach 1
Greymouth 2 Stratford 2
Greytown 1 Taihape 1
Hamilton 9 Taumarunui 2
Hastings 5 Taupō 4
Havelock North 3 Tauranga 8
Hāwera 2 Te Anau 1
Helensville 1 Te Aroha 1
Hibiscus Coast 4 Te Awamutu 2
Hokitika 1 Te Kauwhata 1
Huntly 2 Te Kuiti 2
Inglewood 1 Te Puke 2
Invercargill 5 Temuka 1
Kaiapoi 2 Thames 2
Kaikohe 2 Timaru 4
Kaikōura 1 Tokoroa 3
Kaitaia 2 Tuakau 2
Katikati 1 Turangi 1
Kawerau 2 Upper Hutt 4
Kerikeri 2 Waiheke West 2
Kihikihi 1 Waihi 2
Kumeū-Huapai 1 Waihi Beach-Bowentown 1
Lake Hāwea 1 Waikanae 2
Lake Hayes 1 Waimate 1
Leeston 1 Waipawa 1
Levin 3 Waipukurau 1
Lincoln 1 Wairoa 2
Lower Hutt 7 Waitara 2
Lyttelton 1 Waiuku 2
Mangawhai Heads 1 Wakefield 1
Maraetai 1 Wānaka 2
Martinborough 1 Warkworth 1
Marton 2 Wellington 8
Masterton 3 Wellsford 1
Matamata 2 West Melton 1
Methven 1 Westport 2
Milton 1 Whakatāne 3
Morrinsville 2 Whangamatā 1
Mosgiel 2 Whanganui 5
Motueka 2 Whangārei 5
Murupara 1 Whitianga 2
Napier 6 Winton 1
Nelson 4 Woodend 1
Total Urban   354
Rural areas
Area Number
Northland (Te Tai Tokerau) 18
Auckland (Tāmaki Makaurau) 4
Waikato 43
Bay of Plenty (Te Moana a Toi-te-Huatahi) 23
Tairāwhiti/Hawkes Bay (Te Matau-a-Māui) 20
Taranaki 9
Manawatū/Whanganui    21
Wairarapa/Wellington (Te Whanganui-a-Tara) 2
Nelson (Whakatū)/ Marlborough (Te Tauihu-o-te-waka) 7
Tasman (Te Tai o Aorere)/West Coast (Te Tai Poutini) 26
Canterbury (Waitaha) 22
Otago (Ōtākou)/ Southland (Murihiku) 47
Chatham Islands (Wharekauri / Rēkohu)   1
Great Barrier Island (Aotea) 1
Stewart Island (Rakiura) 1
Total Rural 245
   
Total Urban + Rural 599

Revised Code of Practice for Diagnostic and Interventional Radiology ORS C1

Source: New Zealand Ministry of Health

Privacy

We may publish submissions on the Ministry’s website, unless you have asked us not to. If you are submitting as an individual, we will automatically remove your personal details and any identifiable information. You can chose to have your personal details withheld if your submission is requested under the Official Information Act.

New adverse reactions database will improve and modernise safety monitoring

Source: New Zealand Ministry of Health

Work is now complete on a new state of the art digital database to record details of all adverse reactions to medicines reported to the Centre for Adverse Reactions Monitoring (CARM). The new database will be jointly run by CARM and Medsafe.

“This new digital technology presents the opportunity to transform our existing processes and improve the efficiency and effectiveness of medicine safety monitoring”, says Group Manager of Medsafe, Chris James.

The safety monitoring of the effects of medicines will continue to be conducted jointly by CARM and Medsafe.

“The CARM database has been foundational to the work of CARM and Medsafe, and in recognising the opportunity presented by technology advances and the aging nature of the CARM system, we have worked together with CARM to develop a new state of the art digital solution”, says Chris James.

With work now complete on the full database, Medsafe and CARM are preparing to transition the collection and storage of CARM reports to the new Medsafe database and retire the CARM system.

“These changes will improve the turnaround time for processing adverse reaction reports (ADRs) so that staff at Medsafe and CARM will be able to focus more time on analysing reports, which will contribute to improved signal detection and overall safety monitoring. It also frees CARM of administrative overhead activities, allowing their physicians to focus on the valuable role of medically assessing non-routine reports”, says Michael Tatley, Director of the New Zealand Pharmacovigilance Centre, University of Otago.

An early version of the new system came online in December 2022 to support the processing of ADRs for COVID-19 and Mpox vaccines. The system worked well for staff and since then, work has been ongoing to build and improve upon it.

Aotearoa New Zealand Strategic Framework for Managing COVID-19

Source: New Zealand Ministry of Health

The COVID-19 pandemic has been one of the most significant global events in a generation. It has had far-reaching social, health and economic impacts, well beyond the acute impact on human health. Lives and livelihoods have been disrupted, millions have died worldwide, and for many, the way we work, learn, travel and socialise has changed.

All indications are that COVID-19 will be with us for the foreseeable future. We need to ensure we are well positioned to manage COVID-19 over the long term. We need to build on the gains we have made and have confidence that our systems and communities will be better prepared to respond to future waves of COVID-19, as well as other infectious agents with pandemic potential.  

The Aotearoa New Zealand Strategic Framework for Managing COVID-19 sets out the direction for the long-term management of COVID-19 for our country.  

The COVID-19 virus continues to evolve, as will its impact and our response. This strategic framework builds on and replaces the National Action Plan 3 and the Summary of Aotearoa New Zealand’s Strategic Framework for COVID-19 Variants of Concern – Summary for Cabinet. It is a single framework that outlines the outcomes we seek, and the priorities which will get us there, as we work together on the long-term management of COVID-19. 

Now that the last remaining mandatory COVID-19 measures have been removed, we are shifting our management of COVID-19 from an emergency response, and focusing on improving our resilience to future pandemics and our management of other infectious diseases.   

This strategic framework supports this shift and will harness our efforts toward the high-level goal of pae ora – healthy futures, by protecting Aotearoa New Zealand and the individual and collective wellbeing of our people from the impacts of COVID-19. 

Weaving Insights – Summary report for the Rongoā Workstream

Source: New Zealand Ministry of Health

Summary

Weaving Insights is the summary report for engagement led by Manatū Hauora as part of the rongoā workstream which was progressed alongside the Therapeutic Products Bill. It documents feedback given by Māori at two in-person hui, two virtual hui and an online survey. In total, 295 Māori, provided feedback on the Bill from 17 January to 13 February 2023.

Participants of the rongoā workstream shared a variety of perspectives, including whether they felt the Therapeutic Products Bill protects rongoā, whether it will help assure patient safety and whether it’ll help ensure access to the export market for rongoā.

The rongoā workstream was established on 30 November 2022 by Hon Peeni Henare Associate Minister of Health (Māori) alongside the Therapeutic Products Bill. It was created to explore the interface of the Therapeutic Products Bill and rongoā.

From the beginning, the Government has been clear that it wanted to ensure rongoā was protected. This is why the Minister asked for the stand-alone rongoā workstream. The rongoā workstream was established to develop advice on:

  • the protection of rongoā;
  • the assurance of patient safety; and
  • ensuring access to the export markets for rongoā practitioners providing direct services to patient (alongside those providing therapeutic and products with health benefit claims).

Weaving Insights also includes additional Māori views and perspectives which were heard through the rongoā workstream.

The Therapeutic Products Act was given royal assent on 26 July 2023.

Director-General of Health recommends time-limited pause on the use of female pelvic surgical mesh products to treat stress urinary incontinence

Source: New Zealand Ministry of Health

The Director-General of Health, Dr Diana Sarfati, has supported, effective 23 August 2023, a time-limited pause on the use of surgical mesh for stress urinary incontinence.

The Surgical Mesh Roundtable (MRT), an oversight and monitoring group chaired by Manatū Hauora | Ministry of Health, has been investigating a pause since earlier this year, Dr Sarfati says.

Alongside this, Parliament’s Health Committee recommended in June that Manatū Hauora investigate a pause in the procedure after it considered the petition of Sally Walker, a woman who has been injured by mesh.

The MRT’s assessment is that the balance of benefit and harm from the procedure will be improved by the series of additional measures already planned, and it recommends a pause until those measures are substantively in place.

‘After considering the MRT’s assessment, I have decided to support a pause to allow the following steps to be put in place to reduce the harms linked to the procedure as much as possible,’ Dr Sarfati says.

Those steps are:  

  • providing tailored training and certification for surgeons performing the procedure;  
  • establishing a registry of all public and private patients who could benefit from it;  
  • reviewing patients and the decision to carry out the procedure at multi-disciplinary meetings, which include a range of experts from physiotherapists to surgeons; and  
  • using a structured and guided informed consent process for patients.

‘No surgery is without risks, and it’s important to remember that this particular procedure has changed the lives of many people for the better,’ Dr Sarfati says.

‘However, we recognise it has caused ongoing pain and lessened the quality of life for some people, and we therefore need to act to minimise these outcomes.  

‘We also acknowledge the process has been slow at times and that has potentially added to the frustrations of those who have suffered harm from surgical mesh.’ 

Recognising the length of time to put these measures in place has been a significant factor behind our decision to put in place this time limited pause.

Dr Sarfati says, ‘It is important to note the procedure is paused, not banned. 

‘That means there may be exceptions, and that the procedure might be carried out during the pause if a multi-disciplinary team agree there is no viable alternative. Any use would only happen after extensive consultation and review. 

‘We acknowledge that this pause may cause additional uncertainty for patients awaiting treatment, and concern for those who have recently had it. However, we need to make sure that patients are given treatment that appropriately limits the risk of harm for as many people as possible, and we believe this move will help us achieve that.’

Background

Surgical mesh is a net-like fabric or tape that can be introduced as part of surgery to help repair weakened structures in the human body. As a net-like fabric it is used in the treatment of hernias and historically was also used in the treatment of pelvic organ prolapse (POP). As a tape it is used in the treatment of stress unrinary incontinence. These tapes are frequently known as TVTs (tension-free vaginal tapes) or MUS (mid-urethral slings). Mesh for treatment of POP has not been available for some years. This pause only affects mesh tapes used for stress urinary incontinence.

Urinary incontinence is the unintentional loss of urine. Stress incontinence happens when physical movement puts pressure on your bladder, causing you to leak urine.   

The Ministry recognises that its advice has no legal weight, though it is supported by the Royal Australasian College of Surgeons and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and Medical Council of New Zealand. The recommendation to the sector would likely be considered in any review of complaints against health professionals by health regulatory agencies.  

Alternative treatments for stress urinary incontinence can include surgery without the use of mesh, and non-surgical interventions.  

The Surgical Mesh Roundtable, chaired by the Ministry of Health’s Chief Medical Officer Dr Joe Bourne, will retain oversight on the progress and will provide advice to Manatū Hauora, at the point, a pause can be lifted.

It is difficult to quantity the risks and benefits for these procedures. We know they are successful for many people, and that procedures using mesh have a good outcome for 75% of women, slightly higher than the 70% of good outcomes for women who undergo a non-mesh procedure.

The evidence around risk of harm is more complex. We know that the Health and Disability Commissioner has reported 64 complaints in the past ten years and there is also a 3.6% injury rate for procedures involving mesh based on ACC figures over the past 17 years.

While this incidence is broadly consistent with the international data it is not possible to accurately track how it has changed across those years. 

If people have recently had surgery that involves the use of mesh, the decision would have carefully been considered and was likely to have been the most appropriate option. Most patients have had successful stress urinary incontinence mesh procedures without complications. If people are not experiencing complications, there is no need to take any action.   
  
If a person becomes concerned that they have symptoms which could be related to mesh they should follow up with their medical practitioner. More information about pelvic mesh complications and the symptoms can be found on The New Zealand Female Pelvic Mesh Service. A referral to the NZ Female Pelvic Mesh Service run by Te Whatu Ora is an option to you if you are experiencing any problems that could be related to previous pelvic mesh surgery. 

Precision health: exploring opportunities and challenges to predict, prevent, diagnose, and treat health needs more precisely in Aotearoa New Zealand.

Source: New Zealand Ministry of Health

Summary

The Public Service Act 2020 requires all government departments to produce a LTIB at least once every three years. LTIBs contribute to future decision-making by improving public sector thinking around opportunities and challenges and put such opportunities into the public domain for discussion and debate. LTIBs are independent of Ministers and are not government policy.

Manatū Hauora has published its inaugural Long-term Insights Briefing – Precision health: Exploring opportunities and challenges to predict, prevent, diagnose, and treat health needs more precisely in Aotearoa New Zealand.

‘Precision health’ is an umbrella term for the use of technology and information to develop more precise ways of keeping people healthy. The briefing explores precision health opportunities and challenges through two examples: genomics and artificial intelligence. It also considers areas where changes might be needed to realise the opportunities offered by precision health and to mitigate risks over the next 10 years and beyond.

This document elevates conversations about precision health in Aotearoa New Zealand, with the insights gathered throughout the LTIB’s development providing guidance on what is most important to consider and discuss further. It is also part of a much larger conversation to understand the actions we need to take to ensure all New Zealanders live healthy lives.